Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown cause in a study.

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...